12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Elafin regulatory update

Proteo said FDA granted Orphan Drug designation to Elafin for the treatment of pulmonary arterial hypertension (PAH). Elafin is in preclinical testing for the indication. The natural antagonist of...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >